1-3 of 3
Muriel Meiring
Close
Sort by
Journal Articles

ALX-0081 Nanobody ™ , an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.

Karen Silence, Heidi Jonckheere, Peter Casteels, Jan Roodt, Muriel Meiring, Seb Lamprecht, Martin IJsseldijk, Kristi de Smet, Bob van der Jeugt, Flip de Groot, Torsten Dreier
Journal: Blood
Blood (2006) 108 (11): 896.
https://doi.org/10.1182/blood.V108.11.896.896
Published: 2006
Journal Articles

The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Marc G. Jacquemin, MD, Seb Lamprecht, MSc, Renaud Lavend’homme, MSc, Jan Roodt, MSc, Bernard Chatelain, MD, Veronique Deneys, MD, Jeroen Dewaele, MSc, Jean-Marie Stassen, PhD, Muriel Meiring, PhD, Jean Marie Saint-Remy, MD, Henry Pieters, PhD, Philip Badenhorst, MD
Journal: Blood
Blood (2005) 106 (11): 3200.
https://doi.org/10.1182/blood.V106.11.3200.3200
Published: 2005
Journal Articles

Inhibition of the von Willebrand (VWF)–collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons

Dongmei Wu, Karen Vanhoorelbeke, Nancy Cauwenberghs, Muriel Meiring, Hilde Depraetere, Harry F. Kotze, Hans Deckmyn
Journal: Blood
Blood (2002) 99 (10): 3623–3628.
https://doi.org/10.1182/blood.V99.10.3623
Published: 2002